NGAL: A biomarker of acute and chronic renal dysfunction;La lipocaline NGAL : Biomarqueur d'altération aiguë et chronique de la fonction rénale

Annales de Biologie Clinique

Volumn 69, Issue 6, 2011, Pages 629-636

  Lalanne, Aroune ^a   Beaudeux, Jean Louis ^b,c   Bernard, Marguerite Anne ^a,c  

^a Service de Biochimie Endocrinienne et Oncologique   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

Acute renal failure; Chronic renal failure; Diabetes mellitus; NGAL

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ACUTE KIDNEY FAILURE; BIOLOGICAL MODEL; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; EARLY DIAGNOSIS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; URINE;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; EARLY DIAGNOSIS; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOCALINS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PROTO-ONCOGENE PROTEINS;

EID: 82255173924     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2011.0646     Document Type: Article

References (28)

1. Abergel RJ, Wilson MK, Arceneaux JE, Hoette TM, Strong RK, Byers BR, et al. Anthrax pathogen evades the mammalian immune system through stealth siderophore production. Proc Natl Acad Sci U S A 2006 ; 103 : 18499-503. (Pubitemid 44913439)
2. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004 ; 432 : 917.
3. Schmidt-Ott KM, Mori K. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007 ; 18 : 407-13. (Pubitemid 46193306)
4. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, et al. An iron delivery pathway mediated by a lipocalin. Mol Cel 2002 ; 10 : 1045-56. (Pubitemid 35453824)
5. Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005 ; 123 : 1293-305. (Pubitemid 41821786)
6. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005 ; 115 : 610-21. (Pubitemid 40322235)
7. Challen GA, Martinez G, Davis MJ, Taylor DF, Crowe M, Teasdale RD, et al. Identifying the molecular phenotype of renal progenitor cells. J Am Soc Nephrol 2004 ; 15 : 2344-57. (Pubitemid 39159334)
8. Lameire N, Van Biesen W, Vanholder R. Acute kidney injury. Lancet 2008 ; 372 : 1863-5.
9. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005 ; 365 : 1231-8. (Pubitemid 40469655)
10. Dent CL, Ma Q, Dastrala S, Bennett M, Mitsnefes MM, Barasch J, et al. Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study Crit Care 2007 ; 11 : R127.
11. Nickolas TL, O'Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase - associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008 ; 148 : 810-9. (Pubitemid 351786928)
12. Bennett M, Catherine LD, Ma Q, Dastrala S, Grenier F, Workman R, et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery. A prospective study. Clin J Am Soc Nephrol 2008 ; 3 : 665-73.
13. Bolignano D, Lacquaniti A, Coppoloni G, Donato V, Campo S, Fazio MR, et al. Neutrophil gelatinase-associated lipocaline (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009 ; 4 : 337-44.
14. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 2007 ; 71 : 967-70. (Pubitemid 46741985)
15. Hazem A, Seham B, Eman O, Shereen EG, Waleed M. Serum and urinary NGAL in acute and chronic kidney disease. J Pharma Biomed Sciences (JPBMS) 2011 ; 4 : 4-13.
16. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009 ; 4 : 337-44.
17. Bangert K, Ghiglione M, Uttenthai LO. NGAL is a marker for renal replacement therapy requirement. BioPorto Diagnostics A/S, Gentofte, Denmark and Department of Biochemistry and molecular biology, University of Salamanca, Salamanca, Spain, 19 août 2008, http://www.ngal.com/, consulté le 07/07/2011.
18. Zachwieja J, Soltysiak J, Fichna P, Lipkowska K, StankiewiczW,Skowronska B, et al. Normal-range albuminuria does not exclude nephropathy in diabetic children. Pediatr Nephrol 2010 ; 25 : 1445-51.
19. Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, Lajer M, Hansen PR, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a crosssectional study and the effects of lisinopril. Diabet Med 2010 ; 27 : 1144-5.
20. Thrailkill KM, Moreau CS, Cockrell GE, Jo CH, Bunn RC, Morales-Pozzo AE, et al. Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine 2010 ; 37 : 336-43.
21. Nielsen SE, Hansen HP, Jensen BR, Parving HH, Rossing P. Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study. Nephron Clin Pract 2011 ; 118 : c130-5.
22. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009 ; 32 : 91-8.
23. Yang YH, He XJ, Chen SR, Wang L, Li EM, Xu LY. Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine 2009 ; 36 : 45-51.
24. Santoso JT, Lucci 3rd JA, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 2003 ; 52 : 13-8. (Pubitemid 36920623)
25. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004 ; 24 : 307-15. (Pubitemid 39070114)
26. Gaspari F, Cravedi P, Mandalà M, Perico N, de Leon FR, Stucchi N, et al. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin Pract 2010 ; 115 : c154-60.
27. Hirsch R, Dent C, Pfriem H, Allen J, Beekman 3rd RH, Ma Q, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007 ; 22 : 2089-95. (Pubitemid 350090716)
28. Koura HM, Galal A, Elshamma MF, Kandil DM, Elghorori EA, Khalifa ES. Urinary neutrophil gelatinase-associated lipocalin as a marker of disease activity in patients with lupus nephritis. Int J Acad Res 2011 ; 3 : 141-6.